JP2013518815A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518815A5
JP2013518815A5 JP2012551221A JP2012551221A JP2013518815A5 JP 2013518815 A5 JP2013518815 A5 JP 2013518815A5 JP 2012551221 A JP2012551221 A JP 2012551221A JP 2012551221 A JP2012551221 A JP 2012551221A JP 2013518815 A5 JP2013518815 A5 JP 2013518815A5
Authority
JP
Japan
Prior art keywords
compound
patient
composition
kcnq5
kcnq4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012551221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518815A (ja
JP5844285B2 (ja
Filing date
Publication date
Priority claimed from US12/698,070 external-priority patent/US8993593B2/en
Application filed filed Critical
Publication of JP2013518815A publication Critical patent/JP2013518815A/ja
Publication of JP2013518815A5 publication Critical patent/JP2013518815A5/ja
Application granted granted Critical
Publication of JP5844285B2 publication Critical patent/JP5844285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012551221A 2010-02-01 2011-01-25 カリウムチャネルモジュレーターとしての4−(n−アザシクロアルキル)アニリドの誘導体 Active JP5844285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/698,070 2010-02-01
US12/698,070 US8993593B2 (en) 2006-08-23 2010-02-01 N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PCT/US2011/022345 WO2011094186A1 (en) 2010-02-01 2011-01-25 Derivatives of 4-(n-azacycloalkyl) aniilides as potassium channel modulators

Publications (3)

Publication Number Publication Date
JP2013518815A JP2013518815A (ja) 2013-05-23
JP2013518815A5 true JP2013518815A5 (enExample) 2014-02-27
JP5844285B2 JP5844285B2 (ja) 2016-01-13

Family

ID=44319712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012551221A Active JP5844285B2 (ja) 2010-02-01 2011-01-25 カリウムチャネルモジュレーターとしての4−(n−アザシクロアルキル)アニリドの誘導体

Country Status (12)

Country Link
US (1) US8993593B2 (enExample)
EP (1) EP2531024A4 (enExample)
JP (1) JP5844285B2 (enExample)
KR (1) KR101841989B1 (enExample)
CN (1) CN102869250A (enExample)
AU (1) AU2011209731A1 (enExample)
BR (1) BR112012019199A2 (enExample)
CA (1) CA2788712C (enExample)
EA (1) EA201290748A1 (enExample)
MX (1) MX2012008969A (enExample)
SG (1) SG182799A1 (enExample)
WO (1) WO2011094186A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US20160058895A1 (en) 2013-04-19 2016-03-03 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
MX2018015251A (es) 2016-06-10 2019-04-25 Scifluor Life Sciences Inc Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
IL319015A (en) 2018-05-11 2025-04-01 Xenon Pharmaceuticals Inc Methods for improving bioavailability and exposure of voltage-gated potassium channel openers
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
TWI886158B (zh) * 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) * 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
BR112022010733A2 (pt) * 2019-12-06 2022-08-23 Xenon Pharmaceuticals Inc Métodos para tratar dor
US20210213009A1 (en) * 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂
EP4291185A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
JP7294734B2 (ja) * 2021-10-27 2023-06-20 シャンハイ ジムン バイオファーマ,インコーポレーテッド カリウムチャネル調節剤としての化合物ならびにその調製および応用
WO2023125935A1 (zh) * 2021-12-31 2023-07-06 上海翰森生物医药科技有限公司 苯并哌啶衍生物调节剂、其制备方法和应用
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
EP4536356A1 (en) 2022-06-08 2025-04-16 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators
TW202540067A (zh) * 2024-02-08 2025-10-16 大陸商上海摯盟醫藥科技有限公司 四氫異喹啉基化合物的晶型及其應用
WO2025179128A1 (en) 2024-02-22 2025-08-28 Xenon Pharmaceuticals Inc. Azetukalner for use in the treatment of depression, anhedonia or a seizure disorder such as epilepsy in pediatric subjects
WO2026006669A1 (en) * 2024-06-28 2026-01-02 Xenon Pharmaceuticals Inc. Prodrugs of n-[4-(6-fluoro-3,4-dihydro-2(1 h)-isoquinolinyl)-2,6-dimethylphe nyl]-3,3-dimethyl- butanamide

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US725511A (en) * 1902-10-07 1903-04-14 John Thomson Press Company Apparatus for securing ink-distributing cylinders to platen printing-press.
US3639385A (en) * 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US4181803A (en) * 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) * 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) * 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
AU8071894A (en) * 1994-09-22 1996-04-09 Jonathan M Licht Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US6218411B1 (en) * 1997-08-08 2001-04-17 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetic complications
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6265417B1 (en) * 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
US6395736B1 (en) * 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO2000055137A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
BR0012934A (pt) * 1999-08-04 2003-07-29 Icagen Inc Processos para a redução de dor e de ansiedade
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
EP1208085B1 (en) * 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides as potassium channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) * 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US6984647B2 (en) 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
AU2003303484C1 (en) * 2002-12-23 2012-06-14 Icagen, Inc. Quinazolinones as potassium channel modulators
PT1578740E (pt) 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
WO2004080950A1 (en) 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
SG157231A1 (en) 2003-03-21 2009-12-29 Lundbeck & Co As H Substituted p-diaminobenzene derivatives
WO2004096767A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
AU2004243444A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) * 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
WO2005100349A2 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
WO2006054513A1 (ja) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
WO2008066900A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Similar Documents

Publication Publication Date Title
JP2013518815A5 (enExample)
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
JP2015502346A5 (enExample)
MX359548B (es) Agentes de iarn modificados.
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
WO2010144336A3 (en) Methods for treating chronic kidney disease
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
MX2009001962A (es) Acilanilidas substituidas y metodos de uso de las mismas.
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
JP2015508749A5 (enExample)
MY199027A (en) Method for treating or preventing ophthalmological conditions
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EA201490254A1 (ru) Комбинированное лечение гепатита с
JP2016501219A5 (enExample)
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12013500118A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака